Baudax Bio to Participate at the Oppenheimer 31st Annual Healthcare Conference
10 March 2021 - 11:00PM
Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused
on therapeutics for acute care settings, today announced that Gerri
Henwood, President and Chief Executive Officer, will participate in
a fireside chat at the virtual Oppenheimer 31st Annual Healthcare
Conference on Thursday, March 18, 2021 at 9:20 a.m. ET.
A live webcast of the fireside chat will be
available on the “Presentations” page within the investors section
of the Baudax Bio website at
https://www.baudaxbio.com/news-and-investors. A replay will be made
available for a period of 30 days following the event.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on therapeutics for acute care settings. The launch of Baudax Bio’s
first commercial product ANJESO® began in June 2020 following its
approval by the U.S. Food and Drug Administration in February 2020.
ANJESO is a once daily IV NSAID with preferential Cox-2 activity,
which has successfully completed three Phase III clinical trials,
including two pivotal efficacy trials, a large double-blind Phase
III safety trial and other studies for the management of moderate
to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of
other pharmaceutical assets including two novel neuromuscular
blocking agents (NMBAs) and a proprietary chemical reversal agent
specific to these NMBAs which is currently in preclinical studies,
and intranasal dexmedetomidine which is being developed for
possible uses in pain or sedation. For more information please
visit www.baudaxbio.com.
CONTACT:
Investor Relations Contact:Argot PartnersSam
Martin / Claudia Styslinger(212)
600-1902baudaxbio@argotpartners.com
Media Contact:Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024